

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 11995

EXHIBITS PROVIDED BY THE AMERICAN PHARMACEUTICAL
ASSOCIATION

STATEMENT
OF THE
AMERICAN PHARMACEUTICAL ASSOCIATION
TO THE
SELECT COMMITTEE
ON SMALL BUSINESS
OF THE
UNITED STATES SENATE
94TH CONGRESS, 1ST SESSION
WASHINGTON, D.C.
MARCH 20, 1975

MR. CHAIRMAN, MEMBERS OF THE SUBCOMMITTEE, I AM
DR. WILLIAM S. APPLE, EXECUTIVE DIRECTOR OF THE AMERICAN
PHARMACEUTICAL ASSOCIATION (APHA) WHICH, AS YOU KNOW, IS
THE NATIONAL PROFESSIONAL SOCIETY OF PHARMACISTS IN THE
UNITED STATES. I AM PLEASED, ONCE AGAIN, TO APPEAR BEFORE
THIS DISTINGUISHED COMMITTEE WITH MY ASSOCIATES, DR. EDWARD G.
FELDMANN, ASSOCIATE EXECUTIVE DIRECTOR FOR SCIENTIFIC AFFAIRS,
AND MR. CARL ROBERTS, APHA ASSOCIATE GENERAL COUNSEL.

THIS IS THE THIRD OPPORTUNITY WHICH APHA HAS HAD TO EXPRESS
ITS VIEWS DIRECTLY TO CONGRESS REGARDING THE MAXIMUM ALLOWABLE
COST POLICY ANNOUNCED BY HEW SECRETARY WEINBERGER ON DECEMBER 19,
1973. HOWEVER, IT IS THE FIRST OPPORTUNITY WE HAVE HAD TO
COMMENT ON THE PROPOSED IMPLEMENTATION OF THAT POLICY.